Skip to main content

Market Overview

UPDATE: Jefferies Reiterates On Auxilium Pharmaceuticals, Inc. As Restructuring Realigns Costs With Commercial Opportunities


In a report published Wednesday, Jefferies analyst Thomas Wei reiterated a Buy rating on Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and raised the price target from $32.00 to $34.00.

In the report, Jefferies noted, “AUXL announced today that they would be reducing headcount by 30% and saving roughly $75m annually. Although the company will incur roughly $20m in costs associated with this restructuring, we see it as a net positive for the company given the high SG&A spend relative to peers and dramatic changes in overall Testim market opportunity.”

Auxilium Pharmaceuticals closed on Tuesday at $20.38.

Latest Ratings for AUXL

Oct 2014MizuhoDowngradesBuyNeutral
Oct 2014MKM PartnersDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings


Related Articles (AUXL)

View Comments and Join the Discussion!

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings

Latest Ratings

ICADGuggenheimInitiates Coverage On24.0
SMBKRaymond JamesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at